These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 25868408)

  • 1. The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post-transplantation.
    Patel MS; Kohn R; Kratz JR; Shah JA; Markmann JF; Vagefi PA
    J Am Coll Surg; 2015 Jun; 220(6):1001-7. PubMed ID: 25868408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes utilizing imported liver grafts for recipients with hepatocellular carcinoma.
    Battula N; Reichman TW; Amiri Y; Carmody IC; Galliano G; Seal J; Bugeaud E; Bohorquez H; Bruce D; Cohen A; Loss GE
    Liver Transpl; 2017 Mar; 23(3):299-304. PubMed ID: 28026108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
    Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
    Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".
    Mehta N; Heimbach J; Lee D; Dodge JL; Harnois D; Burns J; Sanchez W; Roberts JP; Yao FY
    Transplantation; 2017 Sep; 101(9):2071-2078. PubMed ID: 28353492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial-ethnic differences in liver transplant waitlist outcomes in patients with hepatocellular carcinoma before and after recent changes to allocation policy.
    Mazur RD; Cron DC; Goldberg DS; Yeh H; Dageforde LA
    Clin Transplant; 2024 Jun; 38(6):e15365. PubMed ID: 38804605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis.
    Lee MW; Raman SS; Asvadi NH; Siripongsakun S; Hicks RM; Chen J; Worakitsitisatorn A; McWilliams J; Tong MJ; Finn RS; Agopian VG; Busuttil RW; Lu DSK
    Hepatology; 2017 Jun; 65(6):1979-1990. PubMed ID: 28170115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.
    Mehta N; Sarkar M; Dodge JL; Fidelman N; Roberts JP; Yao FY
    Liver Transpl; 2016 Feb; 22(2):178-87. PubMed ID: 26479422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of geographic disparity on liver allocation for hepatocellular cancer in the United States.
    Kadry Z; Schaefer EW; Uemura T; Shah AR; Schreibman I; Riley TR
    J Hepatol; 2012 Mar; 56(3):618-25. PubMed ID: 22027581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts.
    Chan SC; Sharr WW; Chok KS; Chan AC; Lo CM
    Transplantation; 2013 Dec; 96(11):995-9. PubMed ID: 23924774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation.
    Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
    Liver Transpl; 2018 Oct; 24(10):1346-1356. PubMed ID: 30067889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States.
    Heimbach JK; Hirose R; Stock PG; Schladt DP; Xiong H; Liu J; Olthoff KM; Harper A; Snyder JJ; Israni AK; Kasiske BL; Kim WR
    Hepatology; 2015 May; 61(5):1643-50. PubMed ID: 25644186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The migrated liver transplantation candidate: insight into geographic disparities in liver distribution.
    Kohn R; Kratz JR; Markmann JF; Vagefi PA
    J Am Coll Surg; 2014 Jun; 218(6):1113-8. PubMed ID: 24680570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Simultaneous Liver Kidney Transplantation in Patients With Hepatocellular Carcinoma.
    Rich N; Tanriover B; Singal AG; Marrero JA
    Transplantation; 2017 Jan; 101(1):e12-e19. PubMed ID: 28009759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone mineral density predicts posttransplant survival among hepatocellular carcinoma liver transplant recipients.
    Sharma P; Parikh ND; Yu J; Barman P; Derstine BA; Sonnenday CJ; Wang SC; Su GL
    Liver Transpl; 2016 Aug; 22(8):1092-8. PubMed ID: 27064263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease.
    Goldberg D; French B; Newcomb C; Liu Q; Sahota G; Wallace AE; Forde KA; Lewis JD; Halpern SD
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1638-1646.e2. PubMed ID: 27374003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on "number of patients needed to transplant" as measure of transplant benefit.
    Vitale A; Cucchetti A; Qiao GL; Cescon M; Li J; Ramirez Morales R; Frigo AC; Xia Y; Tuci F; Shen F; Cillo U; Pinna AD
    J Hepatol; 2014 Jun; 60(6):1165-71. PubMed ID: 24508550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.
    Kwong AJ; Lai JC; Dodge JL; Roberts JP
    Liver Transpl; 2015 Nov; 21(11):1403-9. PubMed ID: 26289624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients From Appalachia Have Reduced Access to Liver Transplantation After Wait-Listing.
    Beal EW; Tumin D; Sobotka L; Tobias JD; Hayes D; Pawlik TM; Washburn K; Mumtaz K; Conteh L; Black SM
    Prog Transplant; 2018 Dec; 28(4):305-313. PubMed ID: 30205758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
    Berry K; Ioannou GN
    Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.